FOXO4-DRI

FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional cells that accumulate with age and drive chronic inflammation. By disrupting the FOXO4-p53 protein interaction that keeps senescent cells alive, FOXO4-DRI triggers apoptosis specifically in senescent cells without affecting healthy surrounding tissue. It represents one of the most targeted senolytic approaches in aging biology research.

Senescent cells resist apoptosis in part because FOXO4 sequesters p53 in the nucleus, preventing p53 from translocating to mitochondria and initiating cell death. FOXO4-DRI is a cell-penetrating peptide that competitively binds FOXO4, disrupting the FOXO4-p53 interaction. This releases p53, allowing it to translocate to the mitochondrial outer membrane where it activates the intrinsic apoptosis pathway via Bax/Bak pore formation and cytochrome c release. Crucially, because healthy cells do not depend on this FOXO4-p53 survival axis, FOXO4-DRI selectively clears senescent cells while leaving non-senescent cells intact. The retro-inverso D-amino acid structure confers protease resistance, enhancing in vivo stability compared to L-peptide equivalents.

The landmark 2017 Cell paper by Baar et al. demonstrated that FOXO4-DRI at 5 mg/kg (IP, every other day x3) restored fitness, hair density, and kidney function in chemotherapy-aged and naturally aged mice. Subsequent studies confirmed senolytic activity in human chondrocytes (relevant to osteoarthritis), senescent Leydig cells (testosterone restoration in aged mice), senescent endothelial cells, and keloid fibroblasts. No human clinical trials have been completed. Pharmacokinetic data in humans — plasma half-life, tissue distribution, clearance — is entirely unknown. Unity Biotechnology has explored senolytic approaches though FOXO4-DRI is not their lead compound.

Peptides commonly paired with FOXO4-DRI for synergistic effects.